Are batroxobin agents effective for perioperative hemorrhage in thoracic surgery? A systematic review of randomized controlled trials

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 2, 2009, Pages 101-107

  Zeng, Zhiyong ^a   Xiao, Pingping ^a   Chen, Junmin ^a   Wei, Yisheng ^b  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b Fujian Institute of Medical Sciences   (China)

Author keywords

Batroxobin agents; Perioperative hemorrhage; Systematic review; Thoracic surgery

Indexed keywords

BATROXOBIN; HEMOGLOBIN;

BLEEDING; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; DATA BASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HEART SURGERY; HUMAN; INTRAOPERATIVE PERIOD; LUNG RESECTION; NAUSEA; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SKIN DISCOMFORT; SYSTEMATIC REVIEW; THORAX SURGERY; TREATMENT OUTCOME; VERTIGO; VOMITING;

BATROXOBIN; BLOOD LOSS, SURGICAL; FIBRINOLYTIC AGENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THORACIC SURGICAL PROCEDURES;

EID: 62349108107     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283254532     Document Type: Review

References (17)

1. Kornalik F. The influence of snake venom enzymes on blood coagulation. Pharmacol Ther 1985; 29:353-405.
2. Matsui T, Fujimura Y, Titani K. Snake venom proteases affecting hemostasis and thrombosis. Biochim Biophys Acts 2000; 1477:146-156.
3. Stocker K, Barlow GH. The coagulant enzyme from Bothrops atrox venom (batroxobin). Methods Enzymol 1976; 45:214-223.
4. Perchuc AM, Menin L, Stocklin R, Buhler B, Schoni R. The potential of Bothrops moojeni venom in the field of hemostasis. Established use and new insights. Pathophysiol Haemost Thromb 2005; 34:241-245.
5. Sugai K, Imamura Y, Mihashi S, Ohba M, Kunikane K, Mori N, et al. Plasma levels and urinary excretion of batroxobin and its defibrinogenating effects in various animal species. J Toxicol Sci 1986; 11:135-143.
6. Wang DS, Hanamoto M, Fang F, Ohba M, Ishii M, Kimura F, et al. Defibrinogenating effect of batroxobin (Defibrase) in rats and inhibition of migration of human vascular smooth muscle cells by the plasma of batroxobin-treated rats in vitro. Atherosclerosis 2001; 158:73-80.
7. Xu G, Liu X, Zhu W, Yin Q, Zhang R, Fan X. Feasibility of treating hyperfibrinogenemia with intermittently administered batroxobin in patients with ischemic stroke/transient ischemic attack for secondary prevention. Blood Coagul Fibrinolysis 2007; 18:193-197.
8. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUORUM statement. Quality of Reporting of Meta-analyses. Lancet 1999; 354:1896-1900.
9. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273:408-412.
10. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17:1-12.
11. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21:1539-1558.
12. Gao XS. Curative effect evaluation of reptilase in operation. J Chin Med Writing 2000; 7:205-206.
13. Wen HM, Lu JL, Liu G, Dai DM, Li HX. Comparison of the effect in preventing bleeding of reptilase and aprotinin used in thoracic operation. Chin J Pract Med 2003; 3:2164-2165.
14. Luan XM. Reptilase and aprotinin to thoracic surgery in pereoperation of clinical effect. Chin J Synth Med 2005; 6:208-209.
15. Yang J, Jiang GN. Hemostatic effect of reptilase on postoperative bleeding in thoracic surgery. China Pharm 2003; 14:356-357.
16. Zhao CL, Wei ZY, Tian MZ, Sun PF, Lai YF, Zheng L. Hemostatic effect of hemocoagulase after cardiopulmonary bypass. Chin J Mod Oper Surg 2004; 8:223-225.
17. Li YM, Ren XY, Huang YJ. The influence of hemocoagulase for injection on blood coagulation during open heart surgery with cardiopulmonary bypass. J Xinjiang Med Univ 2004; 27:56-58.